The HPV Vaccine Leads to a Reduction in Cervical Precancers in Young Women in the U.S.
BACKGROUND AND PURPOSE:
High-grade cervical lesions (CIN2+) are used to monitor HPV vaccine impact, since they develop much more quickly after infection
McClung et al. (MMWR, 2019) used data from the Human Papillomavirus Vaccine Impact Monitoring Project (HPV-IMPACT) to assess the impact of the HPV vaccination program
The following is the first estimate of the number of CIN2+ cases in the U.S. based on population since introduction of the HPV vaccine
Data review and analysis (2008 to 2016)
Data set: HPV-IMPACT
A population-based CIN2+ surveillance system
Age-specific rates applied to U.S. population
data to estimate the total number of CIN2+ cases
An estimated 76% of CIN2+ cases were attributable to HPV types targeted by the vaccine currently used in the US (9-valent HPV vaccine)
The number of CIN2+ cases diagnosed in women aged 18–29 years decreased from 2008 to 2016
2008: ~216,000 (95% CI, 194,000–241,000)
2016: ~196,000 (95% CI, 176,000–221,000)
From 2008 to 2016, the rate of CIN2+ per 100,000 women in the US
Declined significantly in women aged 18–19 years and 20–24 years
Increased significantly in women aged 40–64 years
Rates of cervical precancers have declined in
younger women since the introduction of the vaccine
A majority of CIN2+ cases diagnosed are
attributable to HPV types that the vaccine targets
These changes are likely due to updated cervical
cancer screening and management recommendations, and primary prevention through
Increasing coverage of the vaccine in females at
the routine age of 11-12 years and catch-up vaccination through women 26 years
of age will likely contribute to a further reduction in cervical precancers
Please log in to access ObGFirst and the 2T US Atlas
Media - Internet
Computer System Requirements
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan